v3.25.2
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Long-Lived Assets by Geography The CODM function is regularly provided with the following significant segment expenses:
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Oncology clinical trial related costs$67,824 $19,955 $104,187 $41,852 
Acquired in-process research and development— 15,007 — 15,007 
Compensation related costs, excluding stock-based compensation16,800 10,852 32,654 19,911 
Stock-based compensation478,784 11,088 489,880 20,595 
Other expenses (1)
5,029 2,715 8,567 4,641 
Total segment expenses568,437 59,617 635,288 102,006 
Other income, net2,729 2,334 6,667 4,371 
Interest expense— (3,102)— (6,223)
Net loss$(565,708)$(60,385)$(628,621)$(103,858)
(1) Other expenses include general and administrative expenses excluding compensation and stock-based compensation.